173 related articles for article (PubMed ID: 33703881)
21. Transcriptome-wide differences between Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii: Clues on host survival and probiotic activity based on promoter sequence variability.
Pais P; Oliveira J; Almeida V; Yilmaz M; Monteiro PT; Teixeira MC
Genomics; 2021 Mar; 113(2):530-539. PubMed ID: 33482324
[TBL] [Abstract][Full Text] [Related]
22. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.
Wombwell E; Bransteitter B; Gillen LR
Mycoses; 2021 Dec; 64(12):1521-1526. PubMed ID: 34585799
[TBL] [Abstract][Full Text] [Related]
23. Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial.
Villar-García J; Güerri-Fernández R; Moya A; González A; Hernández JJ; Lerma E; Guelar A; Sorli L; Horcajada JP; Artacho A; D Auria G; Knobel H
PLoS One; 2017; 12(4):e0173802. PubMed ID: 28388647
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
Cui B; Lin L; Wang B; Liu W; Sun C
Pharmacol Res; 2022 Jan; 175():106022. PubMed ID: 34883213
[TBL] [Abstract][Full Text] [Related]
25.
Pais P; Almeida V; Yılmaz M; Teixeira MC
J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32512834
[No Abstract] [Full Text] [Related]
26. Preventive Effect of
Babaei F; Mirzababaei M; Dargahi L; Shahsavari Z; Nassiri-Asl M; Karima S
ACS Chem Neurosci; 2022 Nov; 13(22):3180-3187. PubMed ID: 36318666
[TBL] [Abstract][Full Text] [Related]
27. Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae.
Posteraro B; Sanguinetti M; Romano L; Torelli R; Novarese L; Fadda G
Int J Food Microbiol; 2005 Sep; 103(3):295-304. PubMed ID: 16099314
[TBL] [Abstract][Full Text] [Related]
28. Dissection and enhancement of prebiotic properties of yeast cell wall oligosaccharides through metabolic engineering.
Kwak S; Robinson SJ; Lee JW; Lim H; Wallace CL; Jin YS
Biomaterials; 2022 Mar; 282():121379. PubMed ID: 35078005
[TBL] [Abstract][Full Text] [Related]
29. [Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system].
Stier H; Bischoff SC
MMW Fortschr Med; 2017 Jun; 159(Suppl 5):1-6. PubMed ID: 28643294
[TBL] [Abstract][Full Text] [Related]
30. A Mutation in
Liu JJ; Zhang GC; Kong II; Yun EJ; Zheng JQ; Kweon DH; Jin YS
Appl Environ Microbiol; 2018 May; 84(10):. PubMed ID: 29523547
[TBL] [Abstract][Full Text] [Related]
31. Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii.
Datta S; Timson DJ; Annapure US
J Sci Food Agric; 2017 Jul; 97(9):3039-3049. PubMed ID: 27868205
[TBL] [Abstract][Full Text] [Related]
32. Unique Probiotic Properties and Bioactive Metabolites of Saccharomyces boulardii.
Fu J; Liu J; Wen X; Zhang G; Cai J; Qiao Z; An Z; Zheng J; Li L
Probiotics Antimicrob Proteins; 2023 Aug; 15(4):967-982. PubMed ID: 35608794
[TBL] [Abstract][Full Text] [Related]
33. [Modifying action of Saccharomyces boulardii on the biological properties of enterobacteria].
Kirillov DA; Perunova NB; Chelpachenko OE; Elagina NN; Valyshev AV; Bukharin OV
Zh Mikrobiol Epidemiol Immunobiol; 2002; (4):57-9. PubMed ID: 12449702
[TBL] [Abstract][Full Text] [Related]
34. S-Adenosyl-L-methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death.
Cascio V; Gittings D; Merloni K; Hurton M; Laprade D; Austriaco N
BMC Microbiol; 2013 Feb; 13():35. PubMed ID: 23402325
[TBL] [Abstract][Full Text] [Related]
35. Saccharomyces boulardii CNCM I-745 probiotic does not alter the pharmacokinetics of amoxicillin.
Selig DJ; DeLuca JP; Li Q; Lin H; Nguyen K; Scott SM; Sousa JC; Vuong CT; Xie LH; Livezey JR
Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134728
[TBL] [Abstract][Full Text] [Related]
36. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.
Edwards-Ingram L; Gitsham P; Burton N; Warhurst G; Clarke I; Hoyle D; Oliver SG; Stateva L
Appl Environ Microbiol; 2007 Apr; 73(8):2458-67. PubMed ID: 17293506
[TBL] [Abstract][Full Text] [Related]
37. Non-Saccharomyces yeasts protect against epithelial cell barrier disruption induced by Salmonella enterica subsp. enterica serovar Typhimurium.
Smith IM; Baker A; Arneborg N; Jespersen L
Lett Appl Microbiol; 2015 Nov; 61(5):491-7. PubMed ID: 26280244
[TBL] [Abstract][Full Text] [Related]
38. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
39. Saccharomyces boulardii CNCM I-745 in different clinical conditions.
Dinleyici EC; Kara A; Ozen M; Vandenplas Y
Expert Opin Biol Ther; 2014 Nov; 14(11):1593-609. PubMed ID: 24995675
[TBL] [Abstract][Full Text] [Related]
40. Interaction of Saccharomyces boulardii with intestinal brush border membranes: key to probiotic effects?
Buts JP; De Keyser N
J Pediatr Gastroenterol Nutr; 2010 Oct; 51(4):532-3. PubMed ID: 20706146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
